Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment
The creatinine (Cr)-cystatin C ratio (CCR) at the time of cancer diagnosis is associated with survival; however, to the best of our knowledge, the association between this ratio and mortality in patients with multiple myeloma and renal impairment (RI) is unclear. Therefore, the present study aimed t...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2024-03, Vol.27 (3), p.134, Article 134 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 134 |
| container_title | Oncology letters |
| container_volume | 27 |
| creator | Sun, Yixuan Zhao, Junfeng Du, Jiachen Li, Ying Ding, Fangjie Zhao, Wenbo |
| description | The creatinine (Cr)-cystatin C ratio (CCR) at the time of cancer diagnosis is associated with survival; however, to the best of our knowledge, the association between this ratio and mortality in patients with multiple myeloma and renal impairment (RI) is unclear. Therefore, the present study aimed to assess this association, as well as disease prognosis and the clinical significance of the CCR in patients with multiple myeloma and RI. The present retrospective study included 191 patients diagnosed with multiple myeloma and RI between 2012 and 2022. The predictive value of the CCR was evaluated using area under the receiver operating characteristic curve (AUC) values. The factors affecting overall survival (OS) were assessed using uni- and multivariate logistic regression analyses. The effect of the CCR on survival was evaluated using a Cox regression model and the Kaplan-Meier method. There was a significant association between low CCR and poor progression-free survival (PFS) and overall survival (OS). The 1-, 2- and 3-year PFS and OS rates in patients with a low CCR were significantly lower than those in patients with a high CCR. The 1-, 2- and 3-year AUC values of the CCR were 0.712, 0.764 and 0.746 respectively. Multivariate analysis revealed sex, age, Cr levels, CCR and C-reactive protein levels as independent prognostic factors affecting OS rates. The CCR is a potential prognostic indicator in patients with multiple myeloma with RI and is associated with clinical stages. |
| doi_str_mv | 10.3892/ol.2024.14267 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10867728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A785488315</galeid><sourcerecordid>A785488315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-cdb774a2881c43626c1dc27c81701b7c3824b5f39b64c295c570bbab3bc9517e3</originalsourceid><addsrcrecordid>eNptkk1v3CAQhq2qURMlOfZaIVXqzVsDtsGnKlr1S4rUS3pGGI9jIgwu4K32llPv_Yv5JcG76TYrBQ4M8Mw7mo8se4uLFeUN-ejMihSkXOGS1OxVdoZZQ3JccPL6YLPyNLsM4a5Iq6ox5_Wb7JRyWhNC8Vn2Z2201UoapMfJJCNqZwOStkOTh06rqDeANtLMgFyP4gBIeUiU1RYe7v-qbYjLDa2RX3xRMqdkgI0B_dZxQONsop4MoHELxo1yp-3B7kNK7cfEXmQnvTQBLp_O8-znl88362_59Y-v39dX17kqWRFz1bWMlZJwjlWZUqgV7hRhimNW4JYpyknZVj1t2rpUpKlUxYq2lS1tVVNhBvQ8-7TXneZ2hE6l0F4aMXk9Sr8VTmpx_GP1IG7dRqSi1owRnhTePyl492uGEMWdm33KJgjSEFbUqRfVf-pWGhDa9i6pqVEHJa4Yr0rOKV6o1QtU2h2MWjkLvU7vRw4fnjkMIE0cgjPzrmnHYL4HlXcheOgPKeJCLKMjnBHL6Ijd6CT-3fO6HOh_g0IfAfspwME</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2927061425</pqid></control><display><type>article</type><title>Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment</title><source>PubMed Central</source><creator>Sun, Yixuan ; Zhao, Junfeng ; Du, Jiachen ; Li, Ying ; Ding, Fangjie ; Zhao, Wenbo</creator><creatorcontrib>Sun, Yixuan ; Zhao, Junfeng ; Du, Jiachen ; Li, Ying ; Ding, Fangjie ; Zhao, Wenbo</creatorcontrib><description>The creatinine (Cr)-cystatin C ratio (CCR) at the time of cancer diagnosis is associated with survival; however, to the best of our knowledge, the association between this ratio and mortality in patients with multiple myeloma and renal impairment (RI) is unclear. Therefore, the present study aimed to assess this association, as well as disease prognosis and the clinical significance of the CCR in patients with multiple myeloma and RI. The present retrospective study included 191 patients diagnosed with multiple myeloma and RI between 2012 and 2022. The predictive value of the CCR was evaluated using area under the receiver operating characteristic curve (AUC) values. The factors affecting overall survival (OS) were assessed using uni- and multivariate logistic regression analyses. The effect of the CCR on survival was evaluated using a Cox regression model and the Kaplan-Meier method. There was a significant association between low CCR and poor progression-free survival (PFS) and overall survival (OS). The 1-, 2- and 3-year PFS and OS rates in patients with a low CCR were significantly lower than those in patients with a high CCR. The 1-, 2- and 3-year AUC values of the CCR were 0.712, 0.764 and 0.746 respectively. Multivariate analysis revealed sex, age, Cr levels, CCR and C-reactive protein levels as independent prognostic factors affecting OS rates. The CCR is a potential prognostic indicator in patients with multiple myeloma with RI and is associated with clinical stages.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2024.14267</identifier><identifier>PMID: 38362231</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Bone marrow ; C-reactive protein ; Cancer therapies ; Cardiovascular disease ; Care and treatment ; Chemotherapy ; Creatinine ; Development and progression ; Health aspects ; Hematology ; Hemoglobin ; Medical prognosis ; Medical research ; Medicine, Experimental ; Mortality ; Multiple myeloma ; Multivariate analysis ; Patients ; Plasma ; Prognosis ; Proteins ; Software ; Statistical analysis</subject><ispartof>Oncology letters, 2024-03, Vol.27 (3), p.134, Article 134</ispartof><rights>Copyright: © Sun et al.</rights><rights>COPYRIGHT 2024 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2024</rights><rights>Copyright: © Sun et al. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c470t-cdb774a2881c43626c1dc27c81701b7c3824b5f39b64c295c570bbab3bc9517e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10867728/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10867728/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38362231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Yixuan</creatorcontrib><creatorcontrib>Zhao, Junfeng</creatorcontrib><creatorcontrib>Du, Jiachen</creatorcontrib><creatorcontrib>Li, Ying</creatorcontrib><creatorcontrib>Ding, Fangjie</creatorcontrib><creatorcontrib>Zhao, Wenbo</creatorcontrib><title>Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>The creatinine (Cr)-cystatin C ratio (CCR) at the time of cancer diagnosis is associated with survival; however, to the best of our knowledge, the association between this ratio and mortality in patients with multiple myeloma and renal impairment (RI) is unclear. Therefore, the present study aimed to assess this association, as well as disease prognosis and the clinical significance of the CCR in patients with multiple myeloma and RI. The present retrospective study included 191 patients diagnosed with multiple myeloma and RI between 2012 and 2022. The predictive value of the CCR was evaluated using area under the receiver operating characteristic curve (AUC) values. The factors affecting overall survival (OS) were assessed using uni- and multivariate logistic regression analyses. The effect of the CCR on survival was evaluated using a Cox regression model and the Kaplan-Meier method. There was a significant association between low CCR and poor progression-free survival (PFS) and overall survival (OS). The 1-, 2- and 3-year PFS and OS rates in patients with a low CCR were significantly lower than those in patients with a high CCR. The 1-, 2- and 3-year AUC values of the CCR were 0.712, 0.764 and 0.746 respectively. Multivariate analysis revealed sex, age, Cr levels, CCR and C-reactive protein levels as independent prognostic factors affecting OS rates. The CCR is a potential prognostic indicator in patients with multiple myeloma with RI and is associated with clinical stages.</description><subject>Bone marrow</subject><subject>C-reactive protein</subject><subject>Cancer therapies</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Creatinine</subject><subject>Development and progression</subject><subject>Health aspects</subject><subject>Hematology</subject><subject>Hemoglobin</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mortality</subject><subject>Multiple myeloma</subject><subject>Multivariate analysis</subject><subject>Patients</subject><subject>Plasma</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Software</subject><subject>Statistical analysis</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptkk1v3CAQhq2qURMlOfZaIVXqzVsDtsGnKlr1S4rUS3pGGI9jIgwu4K32llPv_Yv5JcG76TYrBQ4M8Mw7mo8se4uLFeUN-ejMihSkXOGS1OxVdoZZQ3JccPL6YLPyNLsM4a5Iq6ox5_Wb7JRyWhNC8Vn2Z2201UoapMfJJCNqZwOStkOTh06rqDeANtLMgFyP4gBIeUiU1RYe7v-qbYjLDa2RX3xRMqdkgI0B_dZxQONsop4MoHELxo1yp-3B7kNK7cfEXmQnvTQBLp_O8-znl88362_59Y-v39dX17kqWRFz1bWMlZJwjlWZUqgV7hRhimNW4JYpyknZVj1t2rpUpKlUxYq2lS1tVVNhBvQ8-7TXneZ2hE6l0F4aMXk9Sr8VTmpx_GP1IG7dRqSi1owRnhTePyl492uGEMWdm33KJgjSEFbUqRfVf-pWGhDa9i6pqVEHJa4Yr0rOKV6o1QtU2h2MWjkLvU7vRw4fnjkMIE0cgjPzrmnHYL4HlXcheOgPKeJCLKMjnBHL6Ijd6CT-3fO6HOh_g0IfAfspwME</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Sun, Yixuan</creator><creator>Zhao, Junfeng</creator><creator>Du, Jiachen</creator><creator>Li, Ying</creator><creator>Ding, Fangjie</creator><creator>Zhao, Wenbo</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20240301</creationdate><title>Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment</title><author>Sun, Yixuan ; Zhao, Junfeng ; Du, Jiachen ; Li, Ying ; Ding, Fangjie ; Zhao, Wenbo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-cdb774a2881c43626c1dc27c81701b7c3824b5f39b64c295c570bbab3bc9517e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bone marrow</topic><topic>C-reactive protein</topic><topic>Cancer therapies</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Creatinine</topic><topic>Development and progression</topic><topic>Health aspects</topic><topic>Hematology</topic><topic>Hemoglobin</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mortality</topic><topic>Multiple myeloma</topic><topic>Multivariate analysis</topic><topic>Patients</topic><topic>Plasma</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Software</topic><topic>Statistical analysis</topic><toplevel>online_resources</toplevel><creatorcontrib>Sun, Yixuan</creatorcontrib><creatorcontrib>Zhao, Junfeng</creatorcontrib><creatorcontrib>Du, Jiachen</creatorcontrib><creatorcontrib>Li, Ying</creatorcontrib><creatorcontrib>Ding, Fangjie</creatorcontrib><creatorcontrib>Zhao, Wenbo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Yixuan</au><au>Zhao, Junfeng</au><au>Du, Jiachen</au><au>Li, Ying</au><au>Ding, Fangjie</au><au>Zhao, Wenbo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>27</volume><issue>3</issue><spage>134</spage><pages>134-</pages><artnum>134</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>The creatinine (Cr)-cystatin C ratio (CCR) at the time of cancer diagnosis is associated with survival; however, to the best of our knowledge, the association between this ratio and mortality in patients with multiple myeloma and renal impairment (RI) is unclear. Therefore, the present study aimed to assess this association, as well as disease prognosis and the clinical significance of the CCR in patients with multiple myeloma and RI. The present retrospective study included 191 patients diagnosed with multiple myeloma and RI between 2012 and 2022. The predictive value of the CCR was evaluated using area under the receiver operating characteristic curve (AUC) values. The factors affecting overall survival (OS) were assessed using uni- and multivariate logistic regression analyses. The effect of the CCR on survival was evaluated using a Cox regression model and the Kaplan-Meier method. There was a significant association between low CCR and poor progression-free survival (PFS) and overall survival (OS). The 1-, 2- and 3-year PFS and OS rates in patients with a low CCR were significantly lower than those in patients with a high CCR. The 1-, 2- and 3-year AUC values of the CCR were 0.712, 0.764 and 0.746 respectively. Multivariate analysis revealed sex, age, Cr levels, CCR and C-reactive protein levels as independent prognostic factors affecting OS rates. The CCR is a potential prognostic indicator in patients with multiple myeloma with RI and is associated with clinical stages.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>38362231</pmid><doi>10.3892/ol.2024.14267</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2024-03, Vol.27 (3), p.134, Article 134 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10867728 |
| source | PubMed Central |
| subjects | Bone marrow C-reactive protein Cancer therapies Cardiovascular disease Care and treatment Chemotherapy Creatinine Development and progression Health aspects Hematology Hemoglobin Medical prognosis Medical research Medicine, Experimental Mortality Multiple myeloma Multivariate analysis Patients Plasma Prognosis Proteins Software Statistical analysis |
| title | Clinical implications and predictive value of the creatinine‑cystatin C ratio in patients with multiple myeloma and renal impairment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T15%3A23%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20implications%20and%20predictive%20value%20of%20the%20creatinine%E2%80%91cystatin%20C%20ratio%20in%20patients%20with%20multiple%20myeloma%20and%20renal%20impairment&rft.jtitle=Oncology%20letters&rft.au=Sun,%20Yixuan&rft.date=2024-03-01&rft.volume=27&rft.issue=3&rft.spage=134&rft.pages=134-&rft.artnum=134&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2024.14267&rft_dat=%3Cgale_pubme%3EA785488315%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2927061425&rft_id=info:pmid/38362231&rft_galeid=A785488315&rfr_iscdi=true |